Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
2026 Nobel Prize winners announced
It's that time of year again — the first of the 2026 Nobel Prizes have been announced.
NSW Govt to launch science and innovation fund
The fund will be used to coordinate strategic investments, deliver on government priorities and...
DKSH brings Bioyond Robotics' lab automation products Down Under
DKSH will provide distribution of the Bioyond Robotics portfolio of AI-driven autonomous...
